Biotechnology

Acceleron Pharma

$124.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.02%) Today
$0.00 (0.00%) As of 9:00 AM UTC after-hours

Why Robinhood?

You can buy or sell XLRN and other stocks, options, and ETFs commission-free!

About XLRN

Acceleron Pharma Inc. Common Stock, also called Acceleron Pharma, is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. The listed name for XLRN is Acceleron Pharma Inc. Common Stock.

CEO
Habib J. Dable
Employees
237
Headquarters
Cambridge, Massachusetts
Founded
2003
Market Cap
7.62B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
454.94K
High Today
$125.82
Low Today
$123.24
Open Price
$125.16
Volume
261.66K
52 Week High
$136.25
52 Week Low
$50.80

Collections

XLRN Earnings

-$0.95
-$0.63
-$0.32
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, After Hours

You May Also Like

ASEA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure